Fig. 4: AZD4547 exerts tumor suppressive role by inhibiting FGFR2 and YAP1 signaling. | Oncogene

Fig. 4: AZD4547 exerts tumor suppressive role by inhibiting FGFR2 and YAP1 signaling.

From: FGF18–FGFR2 signaling triggers the activation of c-Jun–YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential

Fig. 4

a The IC50 value of AZD4547 in AGS and MGC-803 cells. b Monoclonal colony formation of MGC-803 cells under the treatment of rhFGF18 (50 ng/ml), AZD4547 (5 µM), or AZD4547/rhFGF18, respectively (**p < 0.001). c FGFR and the MEK–ERK signaling were activated by the rhFGF18 stimulation (50 ng/ml) but quenched by AZD4547 (5 µM). d The intensity of migration related F-actin (green) and cell division-related α-Tubulin (red) was analyzed in MGC-803 cells by immunofluorescence staining (scale bar, 20 μm). In the statistical bar chart, 1 to 4 represent vehicle, rhFGF18, AZD4547, and rhFGF18 + AZD4547, respectively. e AZD4547 dose-dependently decreased the downstream targets of YAP1, including CTGF and c-Myc (24 h). f rhFGF18 (50 ng/ml) partly restored CTGF and c-Myc expression in AZD4547 (25 µM for AGS, 5 µM for MGC-803, 25 µM for MKN28) treated cell lines.

Back to article page